Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate

Climacteric

Volumn 1, Issue 3, 1998, Pages 211-218

  Nand, S L ^a   Webster, M A ^a   Baber, R ^b   Heller, G Z ^c  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

Author keywords

Estrone sulfate; Medroxyprogesterone acetate; Menopause

Indexed keywords

DRUG DERIVATIVE; ESTRONE; ESTRONE SULFATE; MEDROXYPROGESTERONE ACETATE;

ADRENERGIC SYSTEM; ADULT; AFFECT; ARTICLE; BREAST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; HEADACHE; HUMAN; LIBIDO; MENOPAUSE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PAIN; RANDOMIZED CONTROLLED TRIAL; VAGINA DISEASE;

ADULT; AFFECT; BREAST; DEPRESSION; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTRONE; FEMALE; HEADACHE; HUMANS; LIBIDO; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; MIDDLE AGED; NAUSEA; PAIN; VAGINAL DISEASES; VASOMOTOR SYSTEM;

EID: 0032169253     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697139809085543     Document Type: Article

References (26)

1. Ziel HK, Finkle WD. Increased risk of endometrial cancer among users of conjugated oestrogens. N Engl J Med 1975;293:1167-70
2. Whitehead MI, Townsend PT, Pryce-Davies J, Ryder TA, King JB. Effects of oestrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599-605
3. Lind T, Cameron EC, Hunter WM, et al. A prospective controlled trial of six forms of hormone replacement therapy given to postmenopausal women. Br J Obstet Gynaecol 1979;86(Suppl): 1-29
4. Hahn R. Compliance considerations with oestrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol 1989;161:1854-8
5. Mattson L-A, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 1982;4: 95-102
6. Jensen J, Riis BJ, Strom V, Christiansen C. Continuous oestrogen-progestogen treatment and serum lipoproteins in postmenopausal women. Br J Obstet Gynaecol 1987;94:130-5
7. MacLennan AH, MacLennan A, Wenzel S, Chambers HM, Eckert K. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust 1993; 159:102-6
8. Clisham PR, de Ziegler D, Lozano K, Judd HL. Comparison of continuous versus sequential oestrogen and progestin therapy in post-menopausal women. Obstet Gynecol 1991;77: 241-6
9. Hawthorn RJ, Spowart K, Walsh D, Hart DM. The endometrial status of women on long-term continuous combined hormone replacement therapy. Br J Obstet Gynaecol 1991;98:939-40
10. William SR, Frencheck B, Speroff T, Speroff L. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. Am J Obstet Gynecol 1990;162:438-46
11. Luciano AA, Turksoy RN, Carleo J, Hendrix JW. Clinical and metabolic responses of menopausal women to sequential versus continuous oestrogen and progestin replacement therapy. Obstet Gynecol 1988;71:39-43
12. Genant HK, Baylink DJ, Gallagher JC, Harris ST, Steiger P, Herber M. Effect of estrone sulphate on postmenopausal bone loss. Obstet Gynecol 1990;76:579-84
13. Nand SL, Webster MA, Baber R, O'Connor V, for The Ogen Provera Study Group. Bleeding pattern and endometrial changes on continuous combined hormone replacement therapy for 2 years. Obstet Gynecol 1998;91:678-84
14. SAS Institute Inc. SAS User's Guide: Statistics, Version 6,1 st edn. Cary, NC: SAS Institute, 1989
15. Diggle PJ, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. Oxford: Oxford University Press, 1994
16. Lobo RA, McCormick W, Singer F, Roy S. Depot MPA compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 1994;3:1-5
17. Schiff I, Tulchinsky D, Cramer D, Ryan KJ. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. J Am Med Assoc 1980; 244:1443-5
18. Paterson MEL. A randomised double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. Br J Obstet Gynaecol 1992;89:464-72
19. Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R, Sandin K. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas 1992; 14:225-36
20. Hilditch JR, Lewis J, Ross AH, et al. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17β combined with an oral progestin on quality of life in postmenopausal women. Maturitas 1996;24:177-84
21. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199-208
22. Speroff L, Rowan J, Symons J, Genant H, Wilborn W, for the CHART Study Group. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy. J Am Med Assoc 1996;276: 1397-403
23. Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol 1997;69:929-32
24. Wren BG, Routledge AD. The effect of type and dose of oestrogen on the blood pressure of postmenopausal women. Maturitas 1983;5:135-42
25. Wing RR, Matthews KA, Kuller LH, Meilahn EN, Plantinga PL. Weight gain at the time of menopause. Arch Intern Med 1991;151:97-102
26. MacLennan AH, MacLennan A, O'Neill S, Kirkgard Y, Wenzel SR, Chamber HM. Oestrogen and cyclical progestogen in postmenopausal hormone replacement therapy. Med J Aust 1992; 157:167-70